Our Platform
A Reusable Scaffold for Antibody Therapeutics
Built around an engineered antibody foundation designed for reduced immunogenicity liability — intended for reuse across multiple programs, targets, and modalities.
Platform Architecture
What the Platform Is
VestraNova's platform centers on a computationally re-engineered antibody scaffold designed to carry reduced predicted MHC-II binding liabilities. Rather than addressing immunogenicity on a per-molecule basis, the platform provides a shared structural starting point intended for adaptation across targets and modalities.
Platform Leverage
What Makes This a Platform
Scaffold-Level Engineering
Modifications operate in the antibody framework region, independent of CDR-mediated antigen binding. The same scaffold is designed to support multiple target specificities.
Computational Validation
Constructs undergo in silico immunogenicity assessment, structural modeling, and stability prediction informed by established computational methods.
Multi-Modality Architecture
The deimmunized Fv domain is designed to function across ADCs, bispecific engagers, radioimmunotherapy, CAR-T, and naked antibody formats.
Broad Population Coverage
Assessed across HLA alleles covering more than 85% of the global population, aiming for therapeutic relevance across diverse patient groups.
Design Principles
How the Platform Works
The platform starts from well-characterized germline frameworks and applies targeted modifications designed to reduce predicted MHC-II binding liabilities. These modifications are positioned to maintain structural integrity, binding function, and manufacturability while aiming to improve the immunogenicity profile of the resulting scaffold.
Therapeutic Reach
Seven Modalities. One Foundation.
The platform is designed to support downstream development across the major antibody-based therapeutic modalities, each built on the same deimmunized scaffold.
Click a modality to learn how VestraNova's scaffold applies
Development Status
Disciplined Development
VestraNova is advancing its lead program and expanding its computationally profiled target portfolio. The company maintains a disciplined approach — clear milestones, structured IP filings, and a focus on building durable platform value rather than rushing individual assets without foundational validation.
Interested in the Platform?
Additional technical and commercial detail is available under NDA for qualified investors, pharma partners, and scientific collaborators.